J Immunother. 2026 Jan 9. doi: 10.1097/CJI.0000000000000597. Online ahead of print.
ABSTRACT
DLGAP5 has emerged as a potential biomarker implicated in tumor progression across various cancers, yet its prognostic value in lung cancer remains to be fully elucidated. In this study, we integrated comprehensive bioinformatics analyses with clinical data to investigate the expression patterns of DLGAP5 and its association with patient outcomes in lung cancer. Expression profiling revealed that DLGAP5 levels varied modestly across clinical subgroups defined by age, sex, tumor stage, and grade, with no statistically significant differences observed. Survival analyses demonstrated that elevated DLGAP5 expression was significantly correlated with reduced overall survival, while disease-free survival showed no marked difference. Multivariate Cox regression and clinical prognostic models further confirmed DLGAP5 as an independent risk factor associated with poorer prognosis (HR=2.35, 95% CI: 1.10-5.03, P=0.021). Functional enrichment analyses of differentially expressed genes between the low-DLGAP5 expression group and high-DLGAP5 expression group identified key biological processes and pathways, including transcriptional regulation and cytoskeletal organization, potentially mediating DLGAP5’s role in lung cancer progression. These findings provide robust evidence supporting the prognostic relevance of DLGAP5 in lung cancer and underscore its potential utility as a therapeutic target.
PMID:41508152 | DOI:10.1097/CJI.0000000000000597
